Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$12.6 million.

  • Oncology Institute's Cash from Operations fell 164212.45% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.8 million, marking a year-over-year increase of 3118.99%. This contributed to the annual value of -$26.5 million for FY2024, which is 2692.28% up from last year.
  • As of Q3 2025, Oncology Institute's Cash from Operations stood at -$12.6 million, which was down 164212.45% from -$10.2 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Cash from Operations registered a high of $4.0 million during Q4 2024, and its lowest value of -$23.3 million during Q4 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$10.2 million (2025), whereas its average is -$9.8 million.
  • Per our database at Business Quant, Oncology Institute's Cash from Operations soared by 171391.3% in 2021 and then plummeted by 375969.83% in 2022.
  • Quarter analysis of 5 years shows Oncology Institute's Cash from Operations stood at -$23.3 million in 2021, then surged by 40.02% to -$14.0 million in 2022, then skyrocketed by 72.19% to -$3.9 million in 2023, then soared by 202.75% to $4.0 million in 2024, then plummeted by 415.75% to -$12.6 million in 2025.
  • Its Cash from Operations stands at -$12.6 million for Q3 2025, versus -$10.2 million for Q2 2025 and -$5.0 million for Q1 2025.